The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Opioids Agonist Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Opioid drugs act on the opioid receptors present in the central and peripheral nervous system. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids.Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges.
The global Opioids Agonist Drugs market size is expected to reach US$ 24650 million by 2029, growing at a CAGR of 2.9% from 2023 to 2029. The market is mainly driven by the significant applications of Opioids Agonist Drugs in various end use industries. The expanding demands from the Pain Management, Cough Treatment and Diarrhea Treatment,, are propelling Opioids Agonist Drugs market. Codeine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Fentanyl segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Opioids Agonist Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Opioids Agonist Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Opioids Agonist Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Opioids Agonist Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Opioids Agonist Drugs covered in this report include Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Egalet Corporation and Endo Pharmaceuticals Inc., etc.
The global Opioids Agonist Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Purdue Pharma
Titan pharmaceuticals
Boehringer Ingelheim
Janssen Pharmaceuticals, Inc
Sanofi
Sun Pharmaceuticals
Mallinckrodt Pharmaceuticals
Egalet Corporation
Endo Pharmaceuticals Inc.
Allergan, Plc
Pfizer Inc
Johnson & Johnson Services, Inc.
Hikma Pharmaceuticals PLC
Grünenthal
AbbVie Inc.
Global Opioids Agonist Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Opioids Agonist Drugs market, Segment by Type:
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Global Opioids Agonist Drugs market, by Application
Pain Management
Cough Treatment
Diarrhea Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Opioids Agonist Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Opioid drugs act on the opioid receptors present in the central and peripheral nervous system. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids.Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges.
The global Opioids Agonist Drugs market size is expected to reach US$ 24650 million by 2029, growing at a CAGR of 2.9% from 2023 to 2029. The market is mainly driven by the significant applications of Opioids Agonist Drugs in various end use industries. The expanding demands from the Pain Management, Cough Treatment and Diarrhea Treatment,, are propelling Opioids Agonist Drugs market. Codeine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Fentanyl segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Opioids Agonist Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Opioids Agonist Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Opioids Agonist Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Opioids Agonist Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Opioids Agonist Drugs covered in this report include Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Egalet Corporation and Endo Pharmaceuticals Inc., etc.
The global Opioids Agonist Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Purdue Pharma
Titan pharmaceuticals
Boehringer Ingelheim
Janssen Pharmaceuticals, Inc
Sanofi
Sun Pharmaceuticals
Mallinckrodt Pharmaceuticals
Egalet Corporation
Endo Pharmaceuticals Inc.
Allergan, Plc
Pfizer Inc
Johnson & Johnson Services, Inc.
Hikma Pharmaceuticals PLC
Grünenthal
AbbVie Inc.
Global Opioids Agonist Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Opioids Agonist Drugs market, Segment by Type:
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Global Opioids Agonist Drugs market, by Application
Pain Management
Cough Treatment
Diarrhea Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Opioids Agonist Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Opioids Agonist Drugs
1.1 Opioids Agonist Drugs Market Overview
1.1.1 Opioids Agonist Drugs Product Scope
1.1.2 Opioids Agonist Drugs Market Status and Outlook
1.2 Global Opioids Agonist Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Opioids Agonist Drugs Market Size by Region (2018-2029)
1.4 Global Opioids Agonist Drugs Historic Market Size by Region (2018-2023)
1.5 Global Opioids Agonist Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Opioids Agonist Drugs Market Size (2018-2029)
1.6.1 North America Opioids Agonist Drugs Market Size (2018-2029)
1.6.2 Europe Opioids Agonist Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Opioids Agonist Drugs Market Size (2018-2029)
1.6.4 Latin America Opioids Agonist Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Opioids Agonist Drugs Market Size (2018-2029)
2 Opioids Agonist Drugs Market by Type
2.1 Introduction
2.1.1 Codeine
2.1.2 Fentanyl
2.1.3 Meperidine
2.1.4 Methadone
2.1.5 Morphine
2.1.6 Hydrocodone
2.2 Global Opioids Agonist Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Opioids Agonist Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Opioids Agonist Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Opioids Agonist Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Opioids Agonist Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Opioids Agonist Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Opioids Agonist Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Opioids Agonist Drugs Revenue Breakdown by Type (2018-2029)
3 Opioids Agonist Drugs Market Overview by Application
3.1 Introduction
3.1.1 Pain Management
3.1.2 Cough Treatment
3.1.3 Diarrhea Treatment
3.2 Global Opioids Agonist Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Opioids Agonist Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Opioids Agonist Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Opioids Agonist Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Opioids Agonist Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Opioids Agonist Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Opioids Agonist Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Opioids Agonist Drugs Revenue Breakdown by Application (2018-2029)
4 Opioids Agonist Drugs Competition Analysis by Players
4.1 Global Opioids Agonist Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioids Agonist Drugs as of 2022)
4.3 Date of Key Players Enter into Opioids Agonist Drugs Market
4.4 Global Top Players Opioids Agonist Drugs Headquarters and Area Served
4.5 Key Players Opioids Agonist Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Opioids Agonist Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Purdue Pharma
5.1.1 Purdue Pharma Profile
5.1.2 Purdue Pharma Main Business
5.1.3 Purdue Pharma Opioids Agonist Drugs Products, Services and Solutions
5.1.4 Purdue Pharma Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Purdue Pharma Recent Developments
5.2 Titan pharmaceuticals
5.2.1 Titan pharmaceuticals Profile
5.2.2 Titan pharmaceuticals Main Business
5.2.3 Titan pharmaceuticals Opioids Agonist Drugs Products, Services and Solutions
5.2.4 Titan pharmaceuticals Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Titan pharmaceuticals Recent Developments
5.3 Boehringer Ingelheim
5.3.1 Boehringer Ingelheim Profile
5.3.2 Boehringer Ingelheim Main Business
5.3.3 Boehringer Ingelheim Opioids Agonist Drugs Products, Services and Solutions
5.3.4 Boehringer Ingelheim Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Janssen Pharmaceuticals, Inc Recent Developments
5.4 Janssen Pharmaceuticals, Inc
5.4.1 Janssen Pharmaceuticals, Inc Profile
5.4.2 Janssen Pharmaceuticals, Inc Main Business
5.4.3 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Products, Services and Solutions
5.4.4 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Janssen Pharmaceuticals, Inc Recent Developments
5.5 Sanofi
5.5.1 Sanofi Profile
5.5.2 Sanofi Main Business
5.5.3 Sanofi Opioids Agonist Drugs Products, Services and Solutions
5.5.4 Sanofi Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Sanofi Recent Developments
5.6 Sun Pharmaceuticals
5.6.1 Sun Pharmaceuticals Profile
5.6.2 Sun Pharmaceuticals Main Business
5.6.3 Sun Pharmaceuticals Opioids Agonist Drugs Products, Services and Solutions
5.6.4 Sun Pharmaceuticals Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Sun Pharmaceuticals Recent Developments
5.7 Mallinckrodt Pharmaceuticals
5.7.1 Mallinckrodt Pharmaceuticals Profile
5.7.2 Mallinckrodt Pharmaceuticals Main Business
5.7.3 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Products, Services and Solutions
5.7.4 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Mallinckrodt Pharmaceuticals Recent Developments
5.8 Egalet Corporation
5.8.1 Egalet Corporation Profile
5.8.2 Egalet Corporation Main Business
5.8.3 Egalet Corporation Opioids Agonist Drugs Products, Services and Solutions
5.8.4 Egalet Corporation Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Egalet Corporation Recent Developments
5.9 Endo Pharmaceuticals Inc.
5.9.1 Endo Pharmaceuticals Inc. Profile
5.9.2 Endo Pharmaceuticals Inc. Main Business
5.9.3 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Products, Services and Solutions
5.9.4 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Endo Pharmaceuticals Inc. Recent Developments
5.10 Allergan, Plc
5.10.1 Allergan, Plc Profile
5.10.2 Allergan, Plc Main Business
5.10.3 Allergan, Plc Opioids Agonist Drugs Products, Services and Solutions
5.10.4 Allergan, Plc Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Allergan, Plc Recent Developments
5.11 Pfizer Inc
5.11.1 Pfizer Inc Profile
5.11.2 Pfizer Inc Main Business
5.11.3 Pfizer Inc Opioids Agonist Drugs Products, Services and Solutions
5.11.4 Pfizer Inc Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Pfizer Inc Recent Developments
5.12 Johnson & Johnson Services, Inc.
5.12.1 Johnson & Johnson Services, Inc. Profile
5.12.2 Johnson & Johnson Services, Inc. Main Business
5.12.3 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Products, Services and Solutions
5.12.4 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Johnson & Johnson Services, Inc. Recent Developments
5.13 Hikma Pharmaceuticals PLC
5.13.1 Hikma Pharmaceuticals PLC Profile
5.13.2 Hikma Pharmaceuticals PLC Main Business
5.13.3 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Products, Services and Solutions
5.13.4 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Hikma Pharmaceuticals PLC Recent Developments
5.14 Grünenthal
5.14.1 Grünenthal Profile
5.14.2 Grünenthal Main Business
5.14.3 Grünenthal Opioids Agonist Drugs Products, Services and Solutions
5.14.4 Grünenthal Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 Grünenthal Recent Developments
5.15 AbbVie Inc.
5.15.1 AbbVie Inc. Profile
5.15.2 AbbVie Inc. Main Business
5.15.3 AbbVie Inc. Opioids Agonist Drugs Products, Services and Solutions
5.15.4 AbbVie Inc. Opioids Agonist Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 AbbVie Inc. Recent Developments
6 North America
6.1 North America Opioids Agonist Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Opioids Agonist Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Opioids Agonist Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Opioids Agonist Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Opioids Agonist Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Opioids Agonist Drugs Market Dynamics
11.1 Opioids Agonist Drugs Industry Trends
11.2 Opioids Agonist Drugs Market Drivers
11.3 Opioids Agonist Drugs Market Challenges
11.4 Opioids Agonist Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
